Ascendis Pharma A/S (ASND), based in Copenhagen, Denmark, is a biopharmaceutical company that utilizes its proprietary TransCon technology platform to develop advanced therapeutics for ...

Novo Nordisk (NVO) has been granted an exclusive worldwide license to Ascendis Pharma’s (ASND) TransCon technology platform to develop its proprietary products in metabolic and cardiovascular ...

“We look forward to working with Ascendis to explore the potential of the TransCon technology platform to reduce the dosing frequency of GLP-1 receptor agonists and other treatments for ...

SKYTROFA® (lonapegsomatropin) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of paediatric ...

Ascendis Pharma A/S (NASDAQ:ASND) Q1 2025 Earnings Call Transcript May 1, 2025 Ascendis Pharma A/S misses on earnings expectations. Reported EPS is $-1.79348 EPS, expectations were $-1.56.

Also Read: Ascendis Pharma’s Rare Dwarfism Candidate Shows Promise In Trial, FDA Submission Expected Next Year The agreement includes provisions requiring certain TransCon technology-based ...

Under deal terms announced Monday, Ascendis, which is also based in Denmark, will conduct early development of the product candidates using its TransCon technology. Novo Nordisk will cover the ...

Ascendis’ ability to apply its TransCon technology platform to build a leading, fully integrated biopharma company, and (iv) Ascendis’ use of its TransCon technologies to create new and ...

Yorvipath utilizes Ascendis’s TransCon technology, which extends the duration of a drug’s action in the body and permits less frequent dosing. The drug was known in development as TransCon PTH.

“We look forward to working with Ascendis to explore the potential of the TransCon technology platform to reduce the dosing frequency of GLP-1 receptor agonists and other treatments for cardiome ...

[2] TransCon refers to "transient conjugation". Ascendis Pharma's innovative technology platform to create new therapies designed to potentially optimise therapeutic effect, including improving ...